Drawing for CAP GT

USPTO serial 79197642

CAP GT

Reviewed by CopyMark Law Group

Reg. 5319386Status 709
Filing date
Status date
Registration date
Oct 31, 2017
Examiner
CORWIN, KEVIN SCOTT
Law office
PUBLICATION AND ISSUE SECTION

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with CAP GT?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Miriam D. Trudell

Miriam D. Trudell Sheridan Ross P.C.1560 Broadway, Suite 1200Denver, CO 80202United States

Goods and services

ClassDescriptionStatusFirst use
001Chemical, biological and biochemical products, preparations and reagents for scientific, research, laboratory, industrial and commercial purposes, except chromatography chemicals and media, and except chemicals for use in separation and purification; chemical, biological and biochemical products, preparations and reagents for researching and characterizing diseases except chromatography chemicals and media, and except chemicals for use in separation and purification; chemical, biological and biochemical products, preparations and reagents for scientific and medical research and drug development except chromatography chemicals and media, and except chemicals for use in separation and purification; chemical, biological and biochemical products, preparations and reagents for manufacturing drugs and pharmaceuticals, except chromatography chemicals and media, and except chemicals for use in separation and purification; micro-organisms, proteins, polypeptides, nucleotides, nucleic acids, eukaryotic cell lines and eukaryotic cells for scientific, research, laboratory, industrial and commercial purposes; all other than for medical or veterinary useSECTION 71 - CANCELLED—
005Medicines for the treatment and prevention of cancer, tumorous diseases, proliferative diseases, allergies, auto-immune diseases, inflammation, inflammatory diseases, infectious diseases, osteoporosis, graft versus host and host versus graft diseases, transplant rejection, coronary heart diseases, minimal residual diseases, restenosis, metabolic disorders, neurological disorders, diabetes, B cell malignancy, rheumatoid arthritis, immunological disorders, parasitic reactions, skin diseases, neurodegenerative diseases and cardio-vascular diseases, except thyreostatics and cough and cold preparations; pharmaceutical and veterinary products, preparations and reagents for the treatment and prevention of cancer, tumorous diseases, proliferative diseases, allergies, auto-immune diseases, inflammation, inflammatory diseases, infectious diseases, osteoporosis, graft versus host and host versus graft diseases, transplant rejection, coronary heart diseases, minimal residual diseases, restenosis, metabolic disorders, neurological disorders, diabetes, B cell malignancy, rheumatoid arthritis, immunological disorders, parasitic reactions, skin diseases, neurodegenerative diseases and cardio-vascular diseases, all afore mentioned goods except thyreostatics and cough and cold preparations; chemical, biological and biochemical preparations for the treatment and prevention of cancer, tumorous diseases, proliferative diseases, allergies, auto-immune diseases, inflammation, inflammatory diseases, infectious diseases, osteoporosis, graft versus host and host versus graft diseases, transplant rejection, coronary heart diseases, minimal residual diseases, restenosis, metabolic disorders, neurological disorders, diabetes, B cell malignancy, rheumatoid arthritis, immunological disorders, parasitic reactions, skin diseases, neurodegenerative diseases and cardio-vascular diseases, preparations and reagents for medical and veterinary purposes for the treatment and prevention of cancer, tumorous diseases, proliferative diseases, allergies, auto-immune diseases, inflammation, inflammatory diseases, infectious diseases, osteoporosis, graft versus host and host versus graft diseases, transplant rejection, coronary heart diseases, minimal residual diseases, restenosis, metabolic disorders, neurological disorders, diabetes, B cell malignancy, rheumatoid arthritis, immunological disorders, parasitic reactions, skin diseases, neurodegenerative diseases and cardio-vascular diseases, except cough and cold preparations, except chromatography chemicals and media, and except chemicals for use in separation and purification; diagnostic and analytical preparations for medical and veterinary purposes for the treatment and prevention of cancer, tumorous diseases, proliferative diseases, allergies, auto-immune diseases, inflammation, inflammatory diseases, infectious diseases, osteoporosis, graft versus host and host versus graft diseases, transplant rejection, coronary heart diseases, minimal residual diseases, restenosis, metabolic disorders, neurological disorders, diabetes, B cell malignancy, rheumatoid arthritis, immunological disorders, parasitic reactions, skin diseases, neurodegenerative diseases and cardio-vascular diseases; cultures of micro-organisms, protein arrays, synthetic polypeptides, nucleotide arrays, nucleic acid sequence, eukaryotic cell lines and eukaryotic cells for medical, veterinary and diagnostic purposes, except cough and cold preparationsSECTION 71 - CANCELLED—
042Scientific and industrial research, in particular in the fields of medicine, pharmacy, molecular biology, biotechnology and genetics; research and development of drugs, diagnostic and analytical preparations, therapy procedures and expression systems; scientific, technical and industrial consultancy, in particular in the field of research medicine, pharmacy, molecular biology, biotechnology and genetics; scientific and industrial research and development of eukaryotic cell lines, eukaryotic cells, micro-organisms, polypeptides, proteins, nucleotides, nucleic acids, for third parties for scientific, research, laboratory development, industrial and commercial purposes, in particular for use in the field of medicine, pharmacy, molecular biology, biotechnology and genetics, except services relating to capture and intermediate purification of proteinsSECTION 71 - CANCELLED—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Apr 26, 2025INNTTOTAL INVALIDATION PROCESSED BY THE IB—
Apr 6, 2025INTSTOTAL INVALIDATION OF REG EXT PROTECTION SENT TO IB—
Apr 5, 2025INPCINVALIDATION PROCESSED—
Jan 18, 2025INTRTOTAL INVALIDATION OF REG EXT PROTECTION CREATED—
Oct 18, 2024NREPNEW REPRESENTATIVE AT IB RECEIVED—
May 17, 2024C71TCANCELLED SECTION 71—
Nov 19, 2023NREPNEW REPRESENTATIVE AT IB RECEIVED—
Aug 21, 2023TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
Aug 21, 2023ECDRTEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS—
Aug 21, 2023EWORTEAS WITHDRAWAL AS DOMESTIC REPRESENTATIVE RECEIVED—
Aug 21, 2023ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Aug 21, 2023REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
Aug 21, 2023CHANAPPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED—
Aug 21, 2023COARTEAS CHANGE OF OWNER ADDRESS RECEIVED—
Oct 31, 2022REM3COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED—
Jul 13, 2021TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
Jul 13, 2021ECDRTEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS—
Jul 13, 2021ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Jul 13, 2021REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
Jun 11, 2021TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
Jun 11, 2021ECDRTEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS—
Jun 11, 2021ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Jun 11, 2021REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
Aug 17, 2018TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
Mar 30, 2018FINOFINAL DECISION TRANSACTION PROCESSED BY IB—
Feb 6, 2018FICSFINAL DISPOSITION NOTICE SENT TO IB—
Feb 6, 2018FIMPFINAL DISPOSITION PROCESSED—
Jan 31, 2018FICRFINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB—
Nov 27, 2017TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
Oct 31, 2017R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Aug 18, 2017GPNXNOTIFICATION PROCESSED BY IB—
Aug 15, 2017NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Aug 15, 2017PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Aug 2, 2017OPNSNOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB—
Aug 2, 2017OP2RNOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB—
Jul 26, 2017NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Jul 11, 2017CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Jun 13, 2017TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Jun 13, 2017CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Jun 13, 2017TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Jan 20, 2017RFNTREFUSAL PROCESSED BY IB—
Dec 30, 2016RFCSNON-FINAL ACTION MAILED - REFUSAL SENT TO IB—
Dec 30, 2016RFRRREFUSAL PROCESSED BY MPU—
Dec 28, 2016RFCRNON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW—
Dec 27, 2016CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Dec 20, 2016MAFRAPPLICATION FILING RECEIPT MAILED—
Dec 15, 2016DOCKASSIGNED TO EXAMINER—
Dec 15, 2016NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Dec 8, 2016REPRSN ASSIGNED FOR SECT 66A APPL FROM IB—

Frequently asked questions

Related guidance